CHICAGO – Merck & Co. Inc. and Dynavax Technologies Corp. have agreed to pursue dual trials investigating the potential for combining immunotherapies from both companies' pipelines to help patients with multiple cancers, an arrangement that could raise visibility for Dynavax at a time when it's also advancing SD-101 on its own.